Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Inflammatory Bowel Diseases

  Free Subscription


Articles published in Aliment Pharmacol Ther

Retrieve available abstracts of 183 articles:
HTML format
Text format



Single Articles


    July 2017
  1. UNGARO RC, Colombel JF
    Editorial: biologics in inflammatory bowel disease-time for direct comparisons.
    Aliment Pharmacol Ther. 2017;46:68-69.
    PubMed     Text format    


  2. ANDREWS JM
    Editorial: yoga for QoL in ulcerative colitis-any better than other supportive activities?
    Aliment Pharmacol Ther. 2017;46:201-202.
    PubMed     Text format    


  3. CRAMER H, Dobos G, Langhorst J
    Editorial: yoga for QoL in ulcerative colitis-any better than other supportive activities? Authors' reply.
    Aliment Pharmacol Ther. 2017;46:202-203.
    PubMed     Text format    


    June 2017
  4. COSTELLO SP, Soo W, Bryant RV, Jairath V, et al
    Systematic review with meta-analysis: faecal microbiota transplantation for the induction of remission for active ulcerative colitis.
    Aliment Pharmacol Ther. 2017 Jun 14. doi: 10.1111/apt.14173.
    PubMed     Text format     Abstract available


  5. AMIOT A, Serrero M, Peyrin-Biroulet L, Filippi J, et al
    One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study.
    Aliment Pharmacol Ther. 2017 Jun 8. doi: 10.1111/apt.14167.
    PubMed     Text format     Abstract available


  6. ALEXAKIS C, Kumar S, Saxena S, Pollok R, et al
    Systematic review and meta-analysis: the impact of a depressive state on disease course in adult inflammatory bowel disease.
    Aliment Pharmacol Ther. 2017 Jun 2. doi: 10.1111/apt.14171.
    PubMed     Text format     Abstract available


  7. D'HAENS GR, Sandborn WJ, Zou G, Stitt LW, et al
    Randomised non-inferiority trial: 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis.
    Aliment Pharmacol Ther. 2017 Jun 1. doi: 10.1111/apt.14164.
    PubMed     Text format     Abstract available


    May 2017
  8. DAMAS OM, Avalos DJ, Palacio AM, Gomez L, et al
    Inflammatory bowel disease is presenting sooner after immigration in more recent US immigrants from Cuba.
    Aliment Pharmacol Ther. 2017 May 19. doi: 10.1111/apt.14145.
    PubMed     Text format     Abstract available


  9. NORTON C, Czuber-Dochan W, Artom M, Sweeney L, et al
    Systematic review: interventions for abdominal pain management in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2017 May 4. doi: 10.1111/apt.14108.
    PubMed     Text format     Abstract available


  10. CHRISTENSEN B, Sparrow MP
    Editorial: international consensus in clinical trial end-points in ulcerative colitis - clarity or just a step in clearing the fog?
    Aliment Pharmacol Ther. 2017;45:1274-1275.
    PubMed     Text format    


  11. LAMBA MJ, Tharayil VS, Gearry RB
    Editorial: inflammatory bowel disease risk reduction after migration - are early life events important?
    Aliment Pharmacol Ther. 2017;45:1367-1368.
    PubMed     Text format    


  12. NELSON A, Tsai HH
    Editorial: Clostridium difficile and inflammatory bowel disease - is it always a bad combination?
    Aliment Pharmacol Ther. 2017;45:1368-1369.
    PubMed     Text format    


  13. EVERHOV AH, Olen O, Ludvigsson JF
    Editorial: importance of definition of inflammatory bowel disease and an increased incidence in children.
    Aliment Pharmacol Ther. 2017;45:1369-1370.
    PubMed     Text format    


  14. HAWTHORNE AB
    Editorial: clinical benefits of vitamin D therapy in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2017;45:1365-1366.
    PubMed     Text format    


    April 2017
  15. RODA G, Narula N, Pinotti R, Skamnelos A, et al
    Systematic review with meta-analysis: proximal disease extension in limited ulcerative colitis.
    Aliment Pharmacol Ther. 2017 Apr 27. doi: 10.1111/apt.14063.
    PubMed     Text format     Abstract available


  16. BYE WA, Jairath V, Travis SPL
    Systematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease.
    Aliment Pharmacol Ther. 2017 Apr 27. doi: 10.1111/apt.14075.
    PubMed     Text format     Abstract available


  17. ROBLIN X, Boschetti G, Williet N, Nancey S, et al
    Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open-label, prospective and randomised clinical trial.
    Aliment Pharmacol Ther. 2017 Apr 27. doi: 10.1111/apt.14106.
    PubMed     Text format     Abstract available


  18. COUGHLAN A, Wylde R, Lafferty L, Quinn S, et al
    A rising incidence and poorer male outcomes characterise early onset paediatric inflammatory bowel disease.
    Aliment Pharmacol Ther. 2017 Apr 27. doi: 10.1111/apt.14070.
    PubMed     Text format     Abstract available


  19. CRAMER H, Schafer M, Schols M, Kocke J, et al
    Randomised clinical trial: yoga vs written self-care advice for ulcerative colitis.
    Aliment Pharmacol Ther. 2017 Apr 5. doi: 10.1111/apt.14062.
    PubMed     Text format     Abstract available


  20. JAIRATH V, Casteele NV, Hindryckx P
    Letter: dose optimising infliximab in acute severe ulcerative colitis - authors' reply.
    Aliment Pharmacol Ther. 2017;45:1170-1171.
    PubMed     Text format    


  21. CHOY MC, De Cruz P
    Letter: dose optimising infliximab in acute severe ulcerative colitis.
    Aliment Pharmacol Ther. 2017;45:1169-1170.
    PubMed     Text format    


  22. ANGELISON L, Marsal J, Hertervig E
    Letter: how to define remission in ulcerative colitis - histological remission should be considered. Authors' reply.
    Aliment Pharmacol Ther. 2017;45:1177-1178.
    PubMed     Text format    


  23. KILINCALP S, Ustun Y, Simsek Z
    Letter: how to define remission in ulcerative colitis - histological remission should be considered.
    Aliment Pharmacol Ther. 2017;45:1177.
    PubMed     Text format    


    March 2017
  24. CHOLAPRANEE A, Hazlewood GS, Kaplan GG, Peyrin-Biroulet L, et al
    Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials.
    Aliment Pharmacol Ther. 2017 Mar 22. doi: 10.1111/apt.14030.
    PubMed     Text format     Abstract available


  25. AKSAN A, Isik H, Radeke HH, Dignass A, et al
    Systematic review with network meta-analysis: comparative efficacy and tolerability of different intravenous iron formulations for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2017 Mar 21. doi: 10.1111/apt.14043.
    PubMed     Text format     Abstract available


  26. SEOW CH, Leung Y, Vande Casteele N, Ehteshami Afshar E, et al
    The effects of pregnancy on the pharmacokinetics of infliximab and adalimumab in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2017 Mar 20. doi: 10.1111/apt.14040.
    PubMed     Text format     Abstract available


  27. BONOVAS S, Fiorino G, Lytras T, Nikolopoulos G, et al
    Systematic review with meta-analysis: use of 5-aminosalicylates and risk of colorectal neoplasia in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2017 Mar 6. doi: 10.1111/apt.14023.
    PubMed     Text format     Abstract available


  28. ARTOM M, Czuber-Dochan W, Norton C
    Letter: causes of fatigue in inflammatory bowel disease remain uncertain - authors' reply.
    Aliment Pharmacol Ther. 2017;45:763-764.
    PubMed     Text format    


  29. GRACIE DJ, Ford AC
    Letter: causes of fatigue in inflammatory bowel disease remain uncertain.
    Aliment Pharmacol Ther. 2017;45:762-763.
    PubMed     Text format    


    February 2017
  30. SMOLINSKA A, Bodelier AG, Dallinga JW, Masclee AA, et al
    The potential of volatile organic compounds for the detection of active disease in patients with ulcerative colitis.
    Aliment Pharmacol Ther. 2017 Feb 26. doi: 10.1111/apt.14004.
    PubMed     Text format     Abstract available


  31. STRIK AS, van den Brink GR, Ponsioen C, Mathot R, et al
    Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2017 Feb 23. doi: 10.1111/apt.13994.
    PubMed     Text format     Abstract available


  32. PORTER CK, Welsh M, Riddle MS, Nieh C, et al
    Epidemiology of inflammatory bowel disease among participants of the Millennium Cohort: incidence, deployment-related risk factors, and antecedent episodes of infectious gastroenteritis.
    Aliment Pharmacol Ther. 2017 Feb 23. doi: 10.1111/apt.13991.
    PubMed     Text format     Abstract available


  33. LOPHAVEN SN, Lynge E, Burisch J
    The incidence of inflammatory bowel disease in Denmark 1980-2013: a nationwide cohort study.
    Aliment Pharmacol Ther. 2017 Feb 23. doi: 10.1111/apt.13971.
    PubMed     Text format     Abstract available


  34. LAW CC, Tariq R, Khanna S, Murthy S, et al
    Systematic review with meta-analysis: the impact of Clostridium difficile infection on the short and long-term risks of colectomy in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2017 Feb 16. doi: 10.1111/apt.13972.
    PubMed     Text format     Abstract available


  35. MAHADEVAN U, Vermeire S, Lasch K, Abhyankar B, et al
    Vedolizumab exposure in pregnancy: outcomes from clinical studies in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2017 Feb 7. doi: 10.1111/apt.13960.
    PubMed     Text format     Abstract available


  36. DOECKE JD, Hartnell F, Bampton P, Bell S, et al
    Infliximab vs. adalimumab in Crohn's disease: results from 327 patients in an Australian and New Zealand observational cohort study.
    Aliment Pharmacol Ther. 2017;45:542-552.
    PubMed     Text format     Abstract available


    January 2017
  37. DIEDEREN K, Hoekman DR, Leek A, Wolters VM, et al
    Raised faecal calprotectin is associated with subsequent symptomatic relapse, in children and adolescents with inflammatory bowel disease in clinical remission.
    Aliment Pharmacol Ther. 2017 Jan 31. doi: 10.1111/apt.13950.
    PubMed     Text format     Abstract available


  38. VUITTON L, Peyrin-Biroulet L, Colombel JF, Pariente B, et al
    Defining endoscopic response and remission in ulcerative colitis clinical trials: an international consensus.
    Aliment Pharmacol Ther. 2017 Jan 23. doi: 10.1111/apt.13948.
    PubMed     Text format     Abstract available


  39. HINDRYCKX P, Novak G, Vande Casteele N, Laukens D, et al
    Review article: dose optimisation of infliximab for acute severe ulcerative colitis.
    Aliment Pharmacol Ther. 2017 Jan 11. doi: 10.1111/apt.13913.
    PubMed     Text format     Abstract available


  40. HARTERY K, O'Reilly S, Houlihan D, Doherty G, et al
    Letter: vedolizumab for the management of inflammatory bowel disease in patients after liver transplantation for primary sclerosing cholangitis.
    Aliment Pharmacol Ther. 2017;45:376-378.
    PubMed     Text format    


  41. HONG SN, Kim HJ, Kim KH, Han SJ, et al
    Risk of incident Mycobacterium tuberculosis infection in patients with inflammatory bowel disease: a nationwide population-based study in South Korea.
    Aliment Pharmacol Ther. 2017;45:253-263.
    PubMed     Text format     Abstract available


    December 2016
  42. ANGELISON L, Almer S, Eriksson A, Karling P, et al
    Long-term outcome of infliximab treatment in chronic active ulcerative colitis: a Swedish multicentre study of 250 patients.
    Aliment Pharmacol Ther. 2016 Dec 27. doi: 10.1111/apt.13893.
    PubMed     Text format     Abstract available


  43. CARRAT F, Seksik P, Colombel JF, Peyrin-Biroulet L, et al
    The effects of aminosalicylates or thiopurines on the risk of colorectal cancer in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2016 Dec 19. doi: 10.1111/apt.13897.
    PubMed     Text format     Abstract available


  44. WONG DR, Coenen MJ, Derijks LJ, Vermeulen SH, et al
    Early prediction of thiopurine-induced hepatotoxicity in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2016 Dec 12. doi: 10.1111/apt.13879.
    PubMed     Text format     Abstract available


    November 2016
  45. ARTOM M, Czuber-Dochan W, Sturt J, Murrells T, et al
    The contribution of clinical and psychosocial factors to fatigue in 182 patients with inflammatory bowel disease: a cross-sectional study.
    Aliment Pharmacol Ther. 2016 Nov 20. doi: 10.1111/apt.13870.
    PubMed     Text format     Abstract available


  46. FEAGAN BG, Patel H, Colombel JF, Rubin DT, et al
    Effects of vedolizumab on health-related quality of life in patients with ulcerative colitis: results from the randomised GEMINI 1 trial.
    Aliment Pharmacol Ther. 2016 Nov 17. doi: 10.1111/apt.13852.
    PubMed     Text format     Abstract available


  47. AGGIO RB, White P, Jayasena H, de Lacy Costello B, et al
    Irritable bowel syndrome and active inflammatory bowel disease diagnosed by faecal gas analysis.
    Aliment Pharmacol Ther. 2016 Nov 10. doi: 10.1111/apt.13822.
    PubMed     Text format     Abstract available


  48. MAO EJ, Hazlewood GS, Kaplan GG, Peyrin-Biroulet L, et al
    Systematic review with meta-analysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn's disease and ulcerative colitis.
    Aliment Pharmacol Ther. 2016 Nov 10. doi: 10.1111/apt.13847.
    PubMed     Text format     Abstract available


  49. COLOMBEL JF, Jharap B, Sandborn WJ, Feagan B, et al
    Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventional therapy.
    Aliment Pharmacol Ther. 2016 Nov 7. doi: 10.1111/apt.13838.
    PubMed     Text format     Abstract available


    October 2016
  50. KIRCHGESNER J, Lemaitre M, Rudnichi A, Racine A, et al
    Therapeutic management of inflammatory bowel disease in real-life practice in the current era of anti-TNF agents: analysis of the French administrative health databases 2009-2014.
    Aliment Pharmacol Ther. 2016 Oct 26. doi: 10.1111/apt.13835.
    PubMed     Text format     Abstract available


  51. SELINGER CP, Carbery I, Warren V, Rehman AF, et al
    The relationship between different information sources and disease-related patient knowledge and anxiety in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2016 Oct 25. doi: 10.1111/apt.13831.
    PubMed     Text format     Abstract available


  52. STALLMACH A, Langbein C, Atreya R, Bruns T, et al
    Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study.
    Aliment Pharmacol Ther. 2016 Oct 7. doi: 10.1111/apt.13813.
    PubMed     Text format     Abstract available


  53. ZHULINA Y, Cao Y, Amcoff K, Carlson M, et al
    Letter: faecal calprotectin for the prediction of relapse in inactive inflammatory bowel disease - authors' reply.
    Aliment Pharmacol Ther. 2016;44:770-1.
    PubMed     Text format    


  54. YAMAMOTO T, Shimoyama T, Kuriyama M
    Letter: faecal calprotectin for the prediction of relapse in inactive inflammatory bowel disease.
    Aliment Pharmacol Ther. 2016;44:769-70.
    PubMed     Text format    


  55. CUI DJ, Chen H, Hu M
    Letter: anti-matrix metalloproteinase-9 monoclonal antibody GS-5745 for ulcerative colitis.
    Aliment Pharmacol Ther. 2016;44:767.
    PubMed     Text format    


    September 2016
  56. D'HAENS G
    Systematic review: second-generation vs. conventional corticosteroids for induction of remission in ulcerative colitis.
    Aliment Pharmacol Ther. 2016 Sep 21. doi: 10.1111/apt.13803.
    PubMed     Text format     Abstract available


    August 2016
  57. PEYRIN-BIROULET L, Germain A, Patel AS, Lindsay JO, et al
    Systematic review: outcomes and post-operative complications following colectomy for ulcerative colitis.
    Aliment Pharmacol Ther. 2016 Aug 17. doi: 10.1111/apt.13763.
    PubMed     Text format     Abstract available


  58. RENNA S, Orlando E, Macaluso FS, Maida M, et al
    Letter: a prospective real life comparison of the efficacy of adalimumab vs. golimumab in moderate to severe ulcerative colitis.
    Aliment Pharmacol Ther. 2016;44:310-1.
    PubMed     Text format    


  59. DIEDEREN K, Hoekman DR, Benninga MA
    Letter: irritable bowel syndrome-type symptoms in paediatric inflammatory bowel disease - authors' reply.
    Aliment Pharmacol Ther. 2016;44:309-10.
    PubMed     Text format    


  60. DAI C, Jiang M, Sun MJ
    Letter: irritable bowel syndrome-type symptoms in paediatric inflammatory bowel disease.
    Aliment Pharmacol Ther. 2016;44:308-9.
    PubMed     Text format    


  61. TRIVEDI PJ, Schmidt C, Bruns T
    Letter: the therapeutic potential of targeting CCL25/CCR9 in colonic inflammatory bowel disease - reading between the lines.
    Aliment Pharmacol Ther. 2016;44:307-8.
    PubMed     Text format    


  62. BROOKS AJ, Rowse G, Ryder A, Peach EJ, et al
    Letter: risk factors and impacts of psychological morbidity in young people with inflammatory bowel disease - authors' reply.
    Aliment Pharmacol Ther. 2016;44:426.
    PubMed     Text format    


  63. QIN HG, Li LQ, Mo HY, Tan JT, et al
    Letter: risk factors and impacts of psychological morbidity in young people with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2016;44:425-6.
    PubMed     Text format    


    July 2016
  64. ZHULINA Y, Cao Y, Amcoff K, Carlson M, et al
    The prognostic significance of faecal calprotectin in patients with inactive inflammatory bowel disease.
    Aliment Pharmacol Ther. 2016 Jul 12. doi: 10.1111/apt.13731.
    PubMed     Text format     Abstract available


  65. CHHAYA V, Saxena S, Cecil E, Subramanian V, et al
    Steroid dependency and trends in prescribing for inflammatory bowel disease - a 20-year national population-based study.
    Aliment Pharmacol Ther. 2016 Jul 4. doi: 10.1111/apt.13700.
    PubMed     Text format     Abstract available


  66. BARREIRO-DE ACOSTA M, Gisbert JP
    Letter: anti-TNF in steroid-dependent ulcerative colitis - are the available data enough?
    Aliment Pharmacol Ther. 2016;44:102.
    PubMed     Text format    


    June 2016
  67. YAMAMOTO T, Shimoyama T, Umegae S, Matsumoto K, et al
    Letter: which patient profile for tacrolimus in ulcerative colitis? Authors' reply.
    Aliment Pharmacol Ther. 2016;43:1243.
    PubMed     Text format    


  68. LAHARIE D, Poullenot F
    Letter: which patient profile for tacrolimus in ulcerative colitis?
    Aliment Pharmacol Ther. 2016;43:1242-3.
    PubMed     Text format    


  69. AHMED I, Greenwood R, Costello B, Ratcliffe N, et al
    Letter: faecal volatile organic metabolites, promising biomarkers in inflammatory bowel disease and Letter: faecal volatile organic metabolites as novel diagnostic biomarkers in inflammatory bowel disease. Authors' reply.
    Aliment Pharmacol Ther. 2016;43:1241-2.
    PubMed     Text format    


  70. FURNARI M, Bodini G, Giannini EG, Savarino V, et al
    Letter: faecal volatile organic metabolites, promising biomarkers in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2016;43:1240-1.
    PubMed     Text format    


  71. SRINIVAS NR
    Letter: faecal volatile organic metabolites as novel diagnostic biomarkers in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2016;43:1239-40.
    PubMed     Text format    


    May 2016
  72. SCHMIDT C, Ahmad T, Tulassay Z, Baumgart DC, et al
    Ferric maltol therapy for iron deficiency anaemia in patients with inflammatory bowel disease: long-term extension data from a Phase 3 study.
    Aliment Pharmacol Ther. 2016 May 29. doi: 10.1111/apt.13665.
    PubMed     Text format     Abstract available


  73. CHEN JH, Andrews JM, Kariyawasam V, Moran N, et al
    Review article: acute severe ulcerative colitis - evidence-based consensus statements.
    Aliment Pharmacol Ther. 2016 May 26. doi: 10.1111/apt.13670.
    PubMed     Text format     Abstract available


  74. SANDBORN WJ, Bhandari BR, Fogel R, Onken J, et al
    Randomised clinical trial: a phase 1, dose-ranging study of the anti-matrix metalloproteinase-9 monoclonal antibody GS-5745 versus placebo for ulcerative colitis.
    Aliment Pharmacol Ther. 2016 May 24. doi: 10.1111/apt.13653.
    PubMed     Text format     Abstract available


  75. TO N, Ford AC, Gracie DJ
    Systematic review with meta-analysis: the effect of tobacco smoking on the natural history of ulcerative colitis.
    Aliment Pharmacol Ther. 2016 May 18. doi: 10.1111/apt.13663.
    PubMed     Text format     Abstract available


  76. BROOKS AJ, Rowse G, Ryder A, Peach EJ, et al
    Systematic review: psychological morbidity in young people with inflammatory bowel disease - risk factors and impacts.
    Aliment Pharmacol Ther. 2016 May 4. doi: 10.1111/apt.13645.
    PubMed     Text format     Abstract available


  77. YAMAMOTO T, Shimoyama T, Umegae S, Matsumoto K, et al
    Editorial: tacrolimus vs. anti-tumour necrosis factor agents for moderately to severely active ulcerative colitis - authors' reply.
    Aliment Pharmacol Ther. 2016;43:1017-8.
    PubMed     Text format    


  78. TAYLOR KM, Sparrow MP
    Editorial: tacrolimus vs. anti-tumour necrosis factor agents for moderately to severely active ulcerative colitis.
    Aliment Pharmacol Ther. 2016;43:1016-7.
    PubMed     Text format    


  79. GISBERT JP, Chaparro M
    Letter: switching from one to another anti-tumour necrosis factor alpha agent, and the risks of an overlap of exposure--authors' reply.
    Aliment Pharmacol Ther. 2016;43:1020.
    PubMed     Text format    


  80. MACALUSO FS, Criscuoli V, Orlando E, Rizzuto G, et al
    Letter: switching from one to another anti-tumour necrosis factor alpha agent, and the risks of an overlap of exposure.
    Aliment Pharmacol Ther. 2016;43:1019-20.
    PubMed     Text format    


  81. BUISSON A, Vazeille E, Minet-Quinard R, Goutte M, et al
    Faecal chitinase 3-like 1 is a reliable marker as accurate as faecal calprotectin in detecting endoscopic activity in adult patients with inflammatory bowel diseases.
    Aliment Pharmacol Ther. 2016;43:1069-79.
    PubMed     Text format     Abstract available


    April 2016
  82. DIEDEREN K, Hoekman DR, Hummel TZ, de Meij TG, et al
    The prevalence of irritable bowel syndrome-type symptoms in paediatric inflammatory bowel disease, and the relationship with biochemical markers of disease activity.
    Aliment Pharmacol Ther. 2016 Apr 25. doi: 10.1111/apt.13636.
    PubMed     Text format     Abstract available


  83. UNGAR B, Mazor Y, Weisshof R, Yanai H, et al
    Induction infliximab levels among patients with acute severe ulcerative colitis compared with patients with moderately severe ulcerative colitis.
    Aliment Pharmacol Ther. 2016 Apr 19. doi: 10.1111/apt.13631.
    PubMed     Text format     Abstract available


  84. LYNCH RW, Churchhouse AM, Protheroe A, Arnott ID, et al
    Predicting outcome in acute severe ulcerative colitis: comparison of the Travis and Ho scores using UK IBD audit data.
    Aliment Pharmacol Ther. 2016 Apr 7. doi: 10.1111/apt.13614.
    PubMed     Text format     Abstract available


  85. BAUMGART DC, Bokemeyer B, Drabik A, Stallmach A, et al
    Vedolizumab induction therapy for inflammatory bowel disease in clinical practice - a nationwide consecutive German cohort study.
    Aliment Pharmacol Ther. 2016 Apr 1. doi: 10.1111/apt.13594.
    PubMed     Text format     Abstract available


  86. KIRCHGESNER J, Sokol H
    Editorial: mongersen in Crohn's disease--a new contribution to the beginning of a long-awaited therapeutic revolution?
    Aliment Pharmacol Ther. 2016;43:838-9.
    PubMed     Text format    


  87. TORRES J, Bao X, Goel A, Colombel JF, et al
    The features of mucosa-associated microbiota in primary sclerosing cholangitis.
    Aliment Pharmacol Ther. 2016;43:790-801.
    PubMed     Text format     Abstract available


    March 2016
  88. SINGH S, Heien HC, Sangaralingham LR, Schilz SR, et al
    Comparative effectiveness and safety of infliximab and adalimumab in patients with ulcerative colitis.
    Aliment Pharmacol Ther. 2016 Mar 15. doi: 10.1111/apt.13580.
    PubMed     Text format     Abstract available


  89. TURSI A, Della Valle N, Penna A, Pranzo G, et al
    Letter: effectiveness of golimumab to induce remission in outpatient ulcerative colitis in Italy.
    Aliment Pharmacol Ther. 2016;43:657-8.
    PubMed     Text format    


  90. ELLUL P, Schembri J, Torpiano P, Borg J, et al
    Letter: abnormal bone densitometry in patients with coeliac disease -beyond malabsorption and sunlight exposure.
    Aliment Pharmacol Ther. 2016;43:658-9.
    PubMed     Text format    


  91. TAYLOR SA
    Editorial: can MRI enterography be an efficient tool for patient selection in clinical trials?
    Aliment Pharmacol Ther. 2016;43:643-4.
    PubMed     Text format    


  92. SIEGEL CA, Dubinsky MC
    Editorial: how to interpret risks and prediction of complications in Crohn's disease--can our patients interpret them? Authors' reply.
    Aliment Pharmacol Ther. 2016;43:653.
    PubMed     Text format    


  93. ROGLER G
    Editorial: how to interpret risks and prediction of complications in Crohn's disease--can our patients interpret them?
    Aliment Pharmacol Ther. 2016;43:651-2.
    PubMed     Text format    


  94. TO N, Gracie DJ, Ford AC
    Systematic review with meta-analysis: the adverse effects of tobacco smoking on the natural history of Crohn's disease.
    Aliment Pharmacol Ther. 2016;43:549-61.
    PubMed     Text format     Abstract available


  95. VEDAK P, Kroshinsky D, St John J, Xavier RJ, et al
    Genetic basis of TNF-alpha antagonist associated psoriasis in inflammatory bowel diseases: a genotype-phenotype analysis.
    Aliment Pharmacol Ther. 2016;43:697-704.
    PubMed     Text format     Abstract available


  96. MONTELEONE G, Di Sabatino A, Ardizzone S, Pallone F, et al
    Impact of patient characteristics on the clinical efficacy of mongersen (GED-0301), an oral Smad7 antisense oligonucleotide, in active Crohn's disease.
    Aliment Pharmacol Ther. 2016;43:717-24.
    PubMed     Text format     Abstract available


    February 2016
  97. KENNEDY NA, Warner B, Johnston EL, Flanders L, et al
    Relapse after withdrawal from anti-TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta-analysis.
    Aliment Pharmacol Ther. 2016 Feb 19. doi: 10.1111/apt.13547.
    PubMed     Text format     Abstract available


  98. MOON W, Loftus EV Jr
    Review article: recent advances in pharmacogenetics and pharmacokinetics for safe and effective thiopurine therapy in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2016 Feb 14. doi: 10.1111/apt.13559.
    PubMed     Text format     Abstract available


  99. MARCHAL BRESSENOT A, Peyrin-Biroulet L
    Letter: histological assessment of disease activity in ulcerative colitis - the problem of score evaluation and validation; authors' reply.
    Aliment Pharmacol Ther. 2016;43:439.
    PubMed     Text format    


  100. VILLANACCI V, Salemme M, Bassotti G, Antonelli E, et al
    Letter: histological assessment of disease activity in ulcerative colitis - the problem of score evaluation and validation.
    Aliment Pharmacol Ther. 2016;43:438-9.
    PubMed     Text format    


  101. DE BIE C, Ferrante M
    Letter: smoking as a modifiable risk factor for a complicated course in Crohn's disease. Authors' reply.
    Aliment Pharmacol Ther. 2016;43:441.
    PubMed     Text format    


  102. TO N, Gracie DJ, Ford AC
    Letter: smoking as a modifiable risk factor for a complicated course in Crohn's disease.
    Aliment Pharmacol Ther. 2016;43:440.
    PubMed     Text format    


  103. SHAH SC, Colombel JF, Sands BE, Narula N, et al
    Systematic review with meta-analysis: mucosal healing is associated with improved long-term outcomes in Crohn's disease.
    Aliment Pharmacol Ther. 2016;43:317-33.
    PubMed     Text format     Abstract available


    January 2016
  104. AHMED I, Greenwood R, Costello B, Ratcliffe N, et al
    Investigation of faecal volatile organic metabolites as novel diagnostic biomarkers in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2016 Jan 25. doi: 10.1111/apt.13522.
    PubMed     Text format     Abstract available


  105. YAMAMOTO T, Shimoyama T, Umegae S, Matsumoto K, et al
    Tacrolimus vs. anti-tumour necrosis factor agents for moderately to severely active ulcerative colitis: a retrospective observational study.
    Aliment Pharmacol Ther. 2016 Jan 13. doi: 10.1111/apt.13531.
    PubMed     Text format     Abstract available


  106. FEVERY J, Van Steenbergen W, Van Pelt J, Laleman W, et al
    Patients with large-duct primary sclerosing cholangitis and Crohn's disease have a better outcome than those with ulcerative colitis, or without IBD.
    Aliment Pharmacol Ther. 2016 Jan 8. doi: 10.1111/apt.13516.
    PubMed     Text format     Abstract available


  107. SEAH D, De Cruz P
    Review article: the practical management of acute severe ulcerative colitis.
    Aliment Pharmacol Ther. 2016 Jan 4. doi: 10.1111/apt.13491.
    PubMed     Text format     Abstract available


  108. AMIOT A, Stefanescu C, Bouhnik Y
    Editorial: what can be done when infliximab stops working in ulcerative colitis? Authors' reply.
    Aliment Pharmacol Ther. 2016;43:165.
    PubMed     Text format    


  109. BOYAPATI RK, Ho GT, Satsangi J
    Editorial: what can be done when infliximab stops working in ulcerative colitis?
    Aliment Pharmacol Ther. 2016;43:164.
    PubMed     Text format    


  110. YAMAMOTO T, Shimoyama T, Matsumoto K
    Letter: wide variation in faecal calprotectin values according to the assay - authors' reply.
    Aliment Pharmacol Ther. 2016;43:178.
    PubMed     Text format    


  111. SUN S, Cavey T, Peltier L, Bendavid C, et al
    Letter: wide variation in faecal calprotectin values according to the assay.
    Aliment Pharmacol Ther. 2016;43:177-8.
    PubMed     Text format    


  112. DE CRUZ P, Kamm MA
    Letter: management of post-operative Crohn's disease - thiopurines vs adalimumab- authors' reply.
    Aliment Pharmacol Ther. 2016;43:170-1.
    PubMed     Text format    


  113. AGUAS M, Nos P, Gisbert JP
    Letter: management of post-operative Crohn's disease - thiopurines vs adalimumab.
    Aliment Pharmacol Ther. 2016;43:168-9.
    PubMed     Text format    


  114. SARTOR RB
    Review article: the potential mechanisms of action of rifaximin in the management of inflammatory bowel diseases.
    Aliment Pharmacol Ther. 2016;43 Suppl 1:27-36.
    PubMed     Text format     Abstract available


  115. DUPONT HL
    Introduction: understanding mechanisms of the actions of rifaximin in selected gastrointestinal diseases.
    Aliment Pharmacol Ther. 2016;43 Suppl 1:1-2.
    PubMed     Text format     Abstract available


  116. COIMBRA AJ, Rimola J, O'Byrne S, Lu TT, et al
    Magnetic resonance enterography is feasible and reliable in multicenter clinical trials in patients with Crohn's disease, and may help select subjects with active inflammation.
    Aliment Pharmacol Ther. 2016;43:61-72.
    PubMed     Text format     Abstract available


  117. DING NS, Hart A, De Cruz P
    Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease - algorithm for practical management.
    Aliment Pharmacol Ther. 2016;43:30-51.
    PubMed     Text format     Abstract available


  118. SIEGEL CA, Horton H, Siegel LS, Thompson KD, et al
    A validated web-based tool to display individualised Crohn's disease predicted outcomes based on clinical, serologic and genetic variables.
    Aliment Pharmacol Ther. 2016;43:262-71.
    PubMed     Text format     Abstract available


    November 2015
  119. FUMERY M, Duricova D, Gower-Rousseau C, Annese V, et al
    Review article: the natural history of paediatric-onset ulcerative colitis in population-based studies.
    Aliment Pharmacol Ther. 2015 Nov 18. doi: 10.1111/apt.13478.
    PubMed     Text format     Abstract available


  120. BOURRIER A, Carrat F, Colombel JF, Bouvier AM, et al
    Excess risk of urinary tract cancers in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study.
    Aliment Pharmacol Ther. 2015 Nov 9. doi: 10.1111/apt.13466.
    PubMed     Text format     Abstract available


  121. GUPTA V, Rodrigues R, Nguyen D, Sauk J, et al
    Adjuvant use of antibiotics with corticosteroids in inflammatory bowel disease exacerbations requiring hospitalisation: a retrospective cohort study and meta-analysis.
    Aliment Pharmacol Ther. 2015 Nov 5. doi: 10.1111/apt.13454.
    PubMed     Text format     Abstract available


  122. BUURMAN DJ, Maurer JM, Keizer RJ, Kosterink JG, et al
    Letter: infliximab therapy for patients with inflammatory bowel disease - some unanswered questions. Authors' reply.
    Aliment Pharmacol Ther. 2015;42:1134.
    PubMed     Text format    


  123. SRINIVAS NR
    Letter: infliximab therapy for patients with inflammatory bowel disease - some unanswered questions.
    Aliment Pharmacol Ther. 2015;42:1133.
    PubMed     Text format    


  124. HAWTHRONE AB
    Editorial: preventing disease progression in Crohn's--can we shut the stable door before the horse bolts?
    Aliment Pharmacol Ther. 2015;42:1131-2.
    PubMed     Text format    


    October 2015
  125. DE BIE C, Ballet V, Hendriks N, Coenen S, et al
    Smoking behaviour and knowledge of the health effects of smoking in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2015 Oct 4. doi: 10.1111/apt.13423.
    PubMed     Text format     Abstract available


  126. CHAPARRO M, Gisbert JP
    Letter: infliximab de-escalation based on trough levels in patients with inflammatory bowel disease - authors' reply.
    Aliment Pharmacol Ther. 2015;42:940-1.
    PubMed     Text format    


  127. PAUL S, Roblin X, Peyrin-Biroulet L
    Letter: infliximab de-escalation based on trough levels in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2015;42:939-40.
    PubMed     Text format    


  128. GUPTA A, De Felice KM, Loftus EV Jr, Khanna S, et al
    Letter: anti-CTLA-4-associated colitis and inflammatory bowel disease pathogenesis - authors' reply.
    Aliment Pharmacol Ther. 2015;42:1032-3.
    PubMed     Text format    


  129. MATUCHANSKY C
    Letter: anti-CTLA-4-associated colitis and inflammatory bowel disease pathogenesis.
    Aliment Pharmacol Ther. 2015;42:1031-2.
    PubMed     Text format    


    September 2015
  130. JAIRATH V, Khanna R, Zou GY, Stitt L, et al
    Development of interim patient-reported outcome measures for the assessment of ulcerative colitis disease activity in clinical trials.
    Aliment Pharmacol Ther. 2015 Sep 21. doi: 10.1111/apt.13408.
    PubMed     Text format     Abstract available


  131. DUMITRESCU G, Amiot A, Seksik P, Baudry C, et al
    The outcome of infliximab dose doubling in 157 patients with ulcerative colitis after loss of response to infliximab.
    Aliment Pharmacol Ther. 2015 Sep 10. doi: 10.1111/apt.13393.
    PubMed     Text format     Abstract available


  132. JHARAP B, Sandborn WJ, Reinisch W, D'Haens G, et al
    Randomised clinical study: discrepancies between patient-reported outcomes and endoscopic appearance in moderate to severe ulcerative colitis.
    Aliment Pharmacol Ther. 2015 Sep 3. doi: 10.1111/apt.13387.
    PubMed     Text format     Abstract available


    August 2015
  133. MARCHAL BRESSENOT A, Riddell RH, Boulagnon-Rombi C, Reinisch W, et al
    Review article: the histological assessment of disease activity in ulcerative colitis.
    Aliment Pharmacol Ther. 2015 Aug 24. doi: 10.1111/apt.13375.
    PubMed     Text format     Abstract available


  134. CHHAYA V, Pollok RC, Cecil E, Subramanian V, et al
    Impact of early thiopurines on surgery in 2770 children and young people diagnosed with inflammatory bowel disease: a national population-based study.
    Aliment Pharmacol Ther. 2015 Aug 13. doi: 10.1111/apt.13361.
    PubMed     Text format     Abstract available


  135. BAN L, Tata LJ, Humes DJ, Fiaschi L, et al
    Decreased fertility rates in 9639 women diagnosed with inflammatory bowel disease: a United Kingdom population-based cohort study.
    Aliment Pharmacol Ther. 2015 Aug 6. doi: 10.1111/apt.13354.
    PubMed     Text format     Abstract available


  136. BUISSON A, Hordonneau C, Goutte M, Boyer L, et al
    Diffusion-weighted magnetic resonance imaging is effective to detect ileocolonic ulcerations in Crohn's disease.
    Aliment Pharmacol Ther. 2015;42:452-60.
    PubMed     Text format     Abstract available


  137. MOON W, Pestana L, Becker B, Loftus EV Jr, et al
    Efficacy and safety of certolizumab pegol for Crohn's disease in clinical practice.
    Aliment Pharmacol Ther. 2015;42:428-40.
    PubMed     Text format     Abstract available


  138. PLUMB AA, Menys A, Russo E, Prezzi D, et al
    Magnetic resonance imaging-quantified small bowel motility is a sensitive marker of response to medical therapy in Crohn's disease.
    Aliment Pharmacol Ther. 2015;42:343-55.
    PubMed     Text format     Abstract available


  139. BEN-HORIN S, Chowers Y, Ungar B, Kopylov U, et al
    Undetectable anti-TNF drug levels in patients with long-term remission predict successful drug withdrawal.
    Aliment Pharmacol Ther. 2015;42:356-64.
    PubMed     Text format     Abstract available


  140. SANDBORN WJ, Melmed GY, McGovern DP, Loftus EV Jr, et al
    Clinical and demographic characteristics predictive of treatment outcomes for certolizumab pegol in moderate to severe Crohn's disease: analyses from the 7-year PRECiSE 3 study.
    Aliment Pharmacol Ther. 2015;42:330-42.
    PubMed     Text format     Abstract available


    July 2015
  141. PUGLIESE D, Guidi L, Ferraro PM, Marzo M, et al
    Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study.
    Aliment Pharmacol Ther. 2015 Jul 31. doi: 10.1111/apt.13352.
    PubMed     Text format     Abstract available


  142. HOURIGAN SK, Chen LA, Grigoryan Z, Laroche G, et al
    Microbiome changes associated with sustained eradication of Clostridium difficile after single faecal microbiota transplantation in children with and without inflammatory bowel disease.
    Aliment Pharmacol Ther. 2015 Jul 21. doi: 10.1111/apt.13326.
    PubMed     Text format     Abstract available


  143. SAFRONEEVA E, Vavricka S, Fournier N, Seibold F, et al
    Systematic analysis of factors associated with progression and regression of ulcerative colitis in 918 patients.
    Aliment Pharmacol Ther. 2015 Jul 6. doi: 10.1111/apt.13307.
    PubMed     Text format     Abstract available


  144. YAMAMOTO T, Shimoyama T, Matsumoto K
    Consecutive monitoring of faecal calprotectin during mesalazine suppository therapy for active rectal inflammation in ulcerative colitis.
    Aliment Pharmacol Ther. 2015 Jul 3. doi: 10.1111/apt.13308.
    PubMed     Text format     Abstract available


  145. CICCOCIOPPO R
    Letter: cytomegalovirus infection in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2015;42:127-9.
    PubMed     Text format    


  146. ROSEN MJ, Minar P, Vinks AA
    Letter: stool adalimumab detection in ulcerative colitis and Crohn's disease - authors' reply.
    Aliment Pharmacol Ther. 2015;42:241.
    PubMed     Text format    


  147. ROBLIN X, Paul S
    Letter: stool adalimumab detection in ulcerative colitis and Crohn's disease.
    Aliment Pharmacol Ther. 2015;42:240.
    PubMed     Text format    


  148. ANANTHAKRISHNAN AN
    Editorial: diabetes and the risk of infections with immunomodulator therapy in inflammatory bowel diseases - author's reply.
    Aliment Pharmacol Ther. 2015;42:120.
    PubMed     Text format    


  149. TAYLOR KM, Sparrow MP
    Editorial: diabetes and the risk of infections with immunomodulator therapy in inflammatory bowel diseases.
    Aliment Pharmacol Ther. 2015;42:119-20.
    PubMed     Text format    


  150. KATSANOS KH, Torres J, Roda G, Brygo A, et al
    Review article: non-malignant oral manifestations in inflammatory bowel diseases.
    Aliment Pharmacol Ther. 2015;42:40-60.
    PubMed     Text format     Abstract available


    June 2015
  151. RUTGEERTS P, Feagan BG, Marano CW, Padgett L, et al
    Randomised clinical trial: a placebo-controlled study of intravenous golimumab induction therapy for ulcerative colitis.
    Aliment Pharmacol Ther. 2015 Jun 29. doi: 10.1111/apt.13291.
    PubMed     Text format     Abstract available


  152. BUURMAN DJ, Maurer JM, Keizer RJ, Kosterink JG, et al
    Population pharmacokinetics of infliximab in patients with inflammatory bowel disease: potential implications for dosing in clinical practice.
    Aliment Pharmacol Ther. 2015 Jun 26. doi: 10.1111/apt.13299.
    PubMed     Text format     Abstract available


  153. LOBATON T, Ferrante M, Rutgeerts P, Ballet V, et al
    Efficacy and safety of anti-TNF therapy in elderly patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2015 Jun 24. doi: 10.1111/apt.13294.
    PubMed     Text format     Abstract available


  154. GISBERT JP, Marin AC, Chaparro M
    Systematic review: factors associated with relapse of inflammatory bowel disease after discontinuation of anti-TNF therapy.
    Aliment Pharmacol Ther. 2015 Jun 15. doi: 10.1111/apt.13276.
    PubMed     Text format     Abstract available


  155. THANGARAJAH D, Hyde MJ, Konteti VK, Santhakumaran S, et al
    Systematic review: body composition in children with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2015 Jun 4. doi: 10.1111/apt.13218.
    PubMed     Text format     Abstract available


  156. BRYANT RV, Andrews JM
    Letter: low muscle mass and disordered eating as causes of osteopenia in inflammatory bowel disease - authors' reply.
    Aliment Pharmacol Ther. 2015;41:1304-5.
    PubMed     Text format    


  157. DEFILIPPIS EM, Webb C, Warren RU, Tabani S, et al
    Letter: low muscle mass and disordered eating as causes of osteopenia in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2015;41:1303-4.
    PubMed     Text format    


  158. ASSIS DN, Levy C
    Editorial: environmental risk factors for PSC with and without IBD--the story unfolds.
    Aliment Pharmacol Ther. 2015;41:1214-6.
    PubMed     Text format    


  159. COLOMBEL JF, Cornillie F, Bevelander G
    Editorial: post hoc analysis of SONIC trial--authors' reply.
    Aliment Pharmacol Ther. 2015;41:1211.
    PubMed     Text format    


  160. FRASER AG
    Editorial: post hoc analysis of SONIC trial.
    Aliment Pharmacol Ther. 2015;41:1210.
    PubMed     Text format    


  161. GISBERT JP, Chaparro M
    Letter: tumour necrosis factor alpha blocker switching--a not so simple pharmacokinetic. Authors' reply.
    Aliment Pharmacol Ther. 2015;41:1302-3.
    PubMed     Text format    


  162. LICINIO R, Losurdo G, Ierardi E, Di Leo A, et al
    Letter: tumour necrosis factor alpha blocker switching--a not so simple pharmacokinetic.
    Aliment Pharmacol Ther. 2015;41:1302.
    PubMed     Text format    


  163. ANANTHAKRISHNAN AN, Cagan A, Cai T, Gainer VS, et al
    Diabetes and the risk of infections with immunomodulator therapy in inflammatory bowel diseases.
    Aliment Pharmacol Ther. 2015;41:1141-8.
    PubMed     Text format     Abstract available


  164. MOJA L, Danese S, Fiorino G, Del Giovane C, et al
    Systematic review with network meta-analysis: comparative efficacy and safety of budesonide and mesalazine (mesalamine) for Crohn's disease.
    Aliment Pharmacol Ther. 2015;41:1055-65.
    PubMed     Text format     Abstract available


    May 2015
  165. ROSARIO M, Dirks NL, Gastonguay MR, Fasanmade AA, et al
    Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease.
    Aliment Pharmacol Ther. 2015 May 20. doi: 10.1111/apt.13243.
    PubMed     Text format     Abstract available


  166. NORTON C, Czuber-Dochan W, Bassett P, Berliner S, et al
    Assessing fatigue in inflammatory bowel disease: comparison of three fatigue scales.
    Aliment Pharmacol Ther. 2015 May 19. doi: 10.1111/apt.13255.
    PubMed     Text format     Abstract available


  167. CASEN C, Vebo HC, Sekelja M, Hegge FT, et al
    Deviations in human gut microbiota: a novel diagnostic test for determining dysbiosis in patients with IBS or IBD.
    Aliment Pharmacol Ther. 2015 May 14. doi: 10.1111/apt.13236.
    PubMed     Text format     Abstract available


  168. LUNNEY PC, Kariyawasam VC, Wang RR, Middleton KL, et al
    Smoking prevalence and its influence on disease course and surgery in Crohn's disease and ulcerative colitis.
    Aliment Pharmacol Ther. 2015 May 12. doi: 10.1111/apt.13239.
    PubMed     Text format     Abstract available


  169. VAN LANGENBERG DR, Papandony MC, Gibson PR
    Sleep and physical activity measured by accelerometry in Crohn's disease.
    Aliment Pharmacol Ther. 2015;41:991-1004.
    PubMed     Text format     Abstract available


    April 2015
  170. CSONTOS AA, Molnar A, Miheller P
    Letter: body surface area and body muscle parameters may influence adalimumab trough levels.
    Aliment Pharmacol Ther. 2015;41:700.
    PubMed     Text format    


  171. KURADA S, Alkhouri N, Fiocchi C, Dweik R, et al
    Letter: volatile metabolomics of exhaled breath or faecal gas? - authors' reply.
    Aliment Pharmacol Ther. 2015;41:704.
    PubMed     Text format    


  172. DE GROOT EF, de Meij TG, van der Schee MP, de Boer NK, et al
    Letter: volatile metabolomics of exhaled breath or faecal gas?
    Aliment Pharmacol Ther. 2015;41:703.
    PubMed     Text format    


  173. GERICH M, Yoon J, Vasiliauskas E
    Editorial: is thalidomide a good option for patients with refractory Crohn's disease? Authors' reply.
    Aliment Pharmacol Ther. 2015;41:786.
    PubMed     Text format    


  174. ROGLER G
    Editorial: is thalidomide a good option for patients with refractory Crohn's disease?
    Aliment Pharmacol Ther. 2015;41:785-6.
    PubMed     Text format    


  175. COLOMBEL JF, Reinisch W, Mantzaris GJ, Kornbluth A, et al
    Randomised clinical trial: deep remission in biologic and immunomodulator naive patients with Crohn's disease - a SONIC post hoc analysis.
    Aliment Pharmacol Ther. 2015;41:734-46.
    PubMed     Text format     Abstract available


    March 2015
  176. SUBRAMANIAM K, Fallon K, Ruut T, Lane D, et al
    Infliximab reverses inflammatory muscle wasting (sarcopenia) in Crohn's disease.
    Aliment Pharmacol Ther. 2015;41:419-28.
    PubMed     Text format     Abstract available


  177. GERICH ME, Yoon JL, Targan SR, Ippoliti AF, et al
    Long-term outcomes of thalidomide in refractory Crohn's disease.
    Aliment Pharmacol Ther. 2015;41:429-37.
    PubMed     Text format     Abstract available


    February 2015
  178. KURADA S, Alkhouri N, Fiocchi C, Dweik R, et al
    Review article: breath analysis in inflammatory bowel diseases.
    Aliment Pharmacol Ther. 2015;41:329-41.
    PubMed     Text format     Abstract available


    January 2015
  179. FELICE C, Lewis A, Armuzzi A, Lindsay JO, et al
    Review article: selective histone deacetylase isoforms as potential therapeutic targets in inflammatory bowel diseases.
    Aliment Pharmacol Ther. 2015;41:26-38.
    PubMed     Text format     Abstract available


  180. KHANNA R, Zou G, D'Haens G, Feagan BG, et al
    A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn's disease activity.
    Aliment Pharmacol Ther. 2015;41:77-86.
    PubMed     Text format     Abstract available


  181. CHURCH PC, Turner D, Feldman BM, Walters TD, et al
    Systematic review with meta-analysis: magnetic resonance enterography signs for the detection of inflammation and intestinal damage in Crohn's disease.
    Aliment Pharmacol Ther. 2015;41:153-66.
    PubMed     Text format     Abstract available


    December 2014
  182. PLENER I, Ferguson C, Kashkooli S, Saibil F, et al
    Oral B12 replacement in Crohn's disease - is B12 by injection obsolete?
    Aliment Pharmacol Ther. 2014;40.
    PubMed     Text format    


    November 2014
  183. LIE MR, Peppelenbosch MP, West RL, Zelinkova Z, et al
    Adalimumab in Crohn's disease patients: pharmacokinetics in the first 6 months of treatment.
    Aliment Pharmacol Ther. 2014;40:1202-8.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Inflammatory Bowel Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: